Avacta Group (AIM:AVCT) - Aandelenkoers, Nieuws & Analyse

AVCT Overzicht aandelen

Avacta Group Plc ontwikkelt geneesmiddelen tegen kanker en in-vitro diagnostica in het Verenigd Koninkrijk, Frankrijk, Noord-Amerika, Zuid-Korea, de rest van Europa en internationaal.

Over het bedrijf

AVCT fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	1/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Beloningen

Revenue is forecast to grow 14.32% per year

Risicoanalyse

Earnings are forecast to decline by an average of 0.4% per year for the next 3 years

Has less than 1 year of cash runway

Highly volatile share price over the past 3 months compared to the UK market

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 1 meer risico

Avacta Group Plc Concurrenten

Bioventix

AIM:BVXP

UK£190.5m

Arecor Therapeutics

AIM:AREC

UK£28.3m

Tissue Regenix Group

AIM:TRX

UK£43.5m

Oxford Biomedica

LSE:OXB

UK£426.7m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Avacta Group
Historische aandelenkoersen
Huidige aandelenkoers	UK£0.54
52 Week Hoogtepunt	UK£1.52
52 Week Laag	UK£0.40
Bèta	1.12
11 maand verandering	9.09%
3 maanden verandering	-11.48%
1 Jaar Verandering	-62.50%
33 jaar verandering	-52.21%
5 jaar verandering	205.08%
Verandering sinds IPO	-86.33%

Recent nieuws en updates

Is Avacta Group (LON:AVCT) Using Debt Sensibly?

Oct 29

Recent updates

Is Avacta Group (LON:AVCT) Using Debt Sensibly?

Oct 29

Avacta Group Plc's (LON:AVCT) 29% Share Price Surge Not Quite Adding Up

Sep 05

Improved Revenues Required Before Avacta Group Plc (LON:AVCT) Shares Find Their Feet

Jun 21

This Is The Reason Why We Think Avacta Group Plc's (LON:AVCT) CEO Deserves A Bump Up To Their Compensation

Jun 22

Avacta Group (LON:AVCT) Is In A Good Position To Deliver On Growth Plans

Jun 20

Avacta Group Plc (LON:AVCT) Insiders Have Been Selling

Feb 18

Companies Like Avacta Group (LON:AVCT) Are In A Position To Invest In Growth

Jan 23

Rendement voor aandeelhouders

	AVCT	GB Biotechs	GB Markt
7D	-2.7%	-0.3%	-1.3%
1Y	-62.5%	-14.6%	8.9%

Rendement versus industrie: AVCT underperformed the UK Biotechs industry which returned -14.6% over the past year.

Rendement versus markt: AVCT underperformed the UK Market which returned 8.9% over the past year.

Prijsvolatiliteit

Is AVCT's price volatile compared to industry and market?
AVCT volatility
AVCT Average Weekly Movement	11.2%
Biotechs Industry Average Movement	8.3%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	9.5%
10% least volatile stocks in GB Market	2.6%

Stabiele aandelenkoers: AVCT's share price has been volatile over the past 3 months compared to the UK market.

Volatiliteit in de loop van de tijd: AVCT's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of UK stocks.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2003	154	Chris Coughlin	www.avacta.com

Avacta Group Plc ontwikkelt geneesmiddelen tegen kanker en in-vitro diagnostica in het Verenigd Koninkrijk, Frankrijk, Noord-Amerika, Zuid-Korea, de rest van Europa en internationaal. Het bedrijf opereert via de segmenten Diagnostica en Therapeutica. Het bedrijf biedt zijn eigen Affimer- en pre|CISION-technologieplatforms aan, die worden gebruikt om een portfolio van gedifferentieerde therapeutische en diagnostische producten te leveren voor verschillende markten.

Avacta Group Plc Samenvatting

Hoe verhouden de winst en inkomsten van Avacta Group zich tot de beurswaarde?
AVCT fundamentele statistieken
Marktkapitalisatie	UK£197.58m
Inkomsten(TTM)	-UK£25.89m
Inkomsten(TTM)	UK£22.62m

8.7x

P/S-verhouding

-7.6x

Koers/Winstverhouding

Is AVCT overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
AVCT resultatenrekening (TTM)
Inkomsten	UK£22.62m
Kosten van inkomsten	UK£13.10m
Brutowinst	UK£9.52m
Overige uitgaven	UK£35.40m
Inkomsten	-UK£25.89m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.071
Brutomarge	42.08%
Nettowinstmarge	-114.45%
Schuld/Eigen Vermogen Verhouding	49.8%

Hoe presteerde AVCT op de lange termijn?

Bekijk historische prestaties en vergelijking

AVCT Overzicht aandelen

Beloningen

Risicoanalyse

Avacta Group Plc Concurrenten

AIM:BVXP

UK£190.5m

AIM:AREC

UK£28.3m

AIM:TRX

UK£43.5m

LSE:OXB

UK£426.7m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Is Avacta Group (LON:AVCT) Using Debt Sensibly?

Avacta Reports Pipeline Advances with Two Novel Programs at the EORTC-NCI-AACR Molecular Targets Symposium in Barcelona

Avacta Group plc Expands Its Pipeline with Two Novel Assets Developed Using Its Pre|CISION Platform

Avacta Group plc Appoints Michelle Morrow as Chief Scientific Officer, Effective November 4, 2024

Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs At 2024 Eortc-Nci-Aacr Symposium

First half 2024 earnings released: UK£0.038 loss per share (vs UK£0.043 loss in 1H 2023)

Recent updates

Is Avacta Group (LON:AVCT) Using Debt Sensibly?

Avacta Reports Pipeline Advances with Two Novel Programs at the EORTC-NCI-AACR Molecular Targets Symposium in Barcelona

Avacta Group plc Expands Its Pipeline with Two Novel Assets Developed Using Its Pre|CISION Platform

Avacta Group plc Appoints Michelle Morrow as Chief Scientific Officer, Effective November 4, 2024

Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs At 2024 Eortc-Nci-Aacr Symposium

First half 2024 earnings released: UK£0.038 loss per share (vs UK£0.043 loss in 1H 2023)

New major risk - Financial position

Avacta Group plc Reports Updated Phase 1 Data of Ava6000 At the European Society for Medical Oncology Congress Demonstrating Multiple Ongoing, Durable Responses in Solid Tumors

Avacta Group Plc to Report First Half, 2024 Results on Sep 30, 2024

Avacta Group Plc's (LON:AVCT) 29% Share Price Surge Not Quite Adding Up

CFO & Company Secretary exercised options and sold UK£305k worth of stock

Avacta Group plc Announces Board Changes

Improved Revenues Required Before Avacta Group Plc (LON:AVCT) Shares Find Their Feet

Avacta Group plc Announces Board Changes

Avacta Group Plc, Annual General Meeting, Jun 26, 2024

Avacta Group plc Announces Successful Completion of First Cohort and Dosing of Three Patients of the Second Cohort in Arm 2 of Avacta's Ava6000 Phase 1 Trial

Avacta Group plc Announces Chief Executive Officer Changes

Avacta Group plc Announces Chief Executive Officer Changes

Full year 2023 earnings: EPS misses analyst expectations

New minor risk - Financial data availability

Avacta Group plc Reports Data from the Ongoing Phase 1 Clinical Trial of AVA6000 At the AACR Annual Meeting

Avacta Group Plc Announces Update on AVA6000 Phase 1a Clinical Trial Progress

Avacta Group Plc has completed a Follow-on Equity Offering in the amount of £5.448474 million.

Avacta Group Plc has filed a Follow-on Equity Offering in the amount of AUD 20.560243 million.

Investors Give Avacta Group Plc (LON:AVCT) Shares A 26% Hiding

Avacta Group plc Announces Appointment of Christina Coughlin as Head of Research and Development and Resignation of Fiona Mclaughlin as Chief Scientific Officer

Avacta Group plc Appoints Simon Bennett as Chief Business Officer of the Therapeutics Division

Price target decreased by 13% to UK£1.38

Avacta Group plc Provides Detailed Pre-Clinical, Clinical and Pharmacokinetic Data from the Phase 1A Dose Escalation Study

First half 2023 earnings released: UK£0.043 loss per share (vs UK£0.036 loss in 1H 2022)

New major risk - Financial position

Avacta Group Plc Announces Management Changes

Avacta Group plc Announces Successful Completion of ALS-6000-101 Sixth Dose Escalation

Avacta Group Plc to Report First Half, 2023 Results on Sep 28, 2023

New minor risk - Share price stability

Getting In Cheap On Avacta Group Plc (LON:AVCT) Is Unlikely

Avacta Announces Successful Completion of Fifth Dose Escalation in Ava6000 Phase 1 Clinical Study

Would Avacta Group (LON:AVCT) Be Better Off With Less Debt?

Avacta Group plc Appoints Shaun Chilton to the Board as Non-Executive Director

Avacta Group Plc (AIM:AVCT) acquired Unknown minority stake in AffyXell Therapeutics Co., Ltd. from Daewoong pharmaceutical Co.,Ltd (KOSE:A069620).

Avacta Group Plc, Annual General Meeting, Jun 28, 2023

Avacta Group plc acquired Coris Bioconcept SRL for £10.4 million.

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Avacta Group plc Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study

Price target decreased to UK£1.55

High number of new and inexperienced directors

Price target decreased to UK£1.55

Avacta Group Plc (AIM:AVCT) conditionally agreed to acquire Launch Diagnostics Holdings Limited for £37 million.

First half 2022 earnings released: UK£0.036 loss per share (vs UK£0.041 loss in 1H 2021)

Avacta Group Plc to Report First Half, 2022 Results on Sep 29, 2022

Avacta Group plc Announces Phase I Study of AVA6000 Advances to Fourth Cohort

High number of new and inexperienced directors

Avacta Group Plc announced that it has received funding

Avacta Group Plc Announces Second Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-Doxorubicin

Avacta Group Plc, Annual General Meeting, Jun 23, 2022

Avacta Group Plc Relocates its Therapeutics Division to New Headquarters at Scale Space, in Imperial College's White City Campus, London

Less than half of directors are independent

Full year 2021 earnings released: UK£0.11 loss per share (vs UK£0.084 loss in FY 2020)

Avacta Group Plc to Report Fiscal Year 2021 Results on Apr 06, 2022